Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ... Journal of clinical oncology 33 (3), 244, 2015 | 1898 | 2015 |
Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1811 | 2016 |
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1591 | 2017 |
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases F Saad, JE Brown, C Van Poznak, T Ibrahim, SM Stemmer, AT Stopeck, ... Annals of oncology 23 (5), 1341-1347, 2012 | 926 | 2012 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 748 | 2018 |
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer … R Herrmann, G Bodoky, T Ruhstaller, B Glimelius, E Bajetta, J Schuller, ... Journal of Clinical Oncology 25 (16), 2212-2217, 2007 | 748 | 2007 |
Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood … EJ Shpall, RB Jones, SI Bearman, WA Franklin, PG Archer, T Curiel, ... Journal of Clinical Oncology 12 (1), 28-36, 1994 | 484 | 1994 |
Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple … J Baselga, P Gómez, R Greil, S Braga, MA Climent, AM Wardley, ... Journal of clinical oncology 31 (20), 2586-2592, 2013 | 442 | 2013 |
The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy R Scherz-Shouval, S Santagata, ML Mendillo, LM Sholl, I Ben-Aharon, ... Cell 158 (3), 564-578, 2014 | 380 | 2014 |
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 370 | 2017 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial B Bockorny, V Semenisty, T Macarulla, E Borazanci, BM Wolpin, ... Nature Medicine 26 (6), 878-885, 2020 | 354 | 2020 |
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ... Gynecologic oncology 140 (2), 199-203, 2016 | 303 | 2016 |
Overall survival with ribociclib plus letrozole in advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, L Hart, ... New England Journal of Medicine 386 (10), 942-950, 2022 | 300 | 2022 |
Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer A Massarweh, N Eliakim-Raz, A Stemmer, A Levy-Barda, S Yust-Katz, ... JAMA oncology 7 (8), 1133-1140, 2021 | 264 | 2021 |
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials L Bonilla, I Ben-Aharon, L Vidal, A Gafter-Gvili, L Leibovici, SM Stemmer Journal of the National Cancer Institute 102 (24), 1845-1854, 2010 | 258 | 2010 |
Interventions for alleviating cancer-related dyspnea: a systematic review I Ben-Aharon, A Gafter-Gvili, M Paul, L Leibovici, SM Stemmer Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2008 | 217 | 2008 |
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 214 | 2023 |
Doxorubicin-induced ovarian toxicity I Ben-Aharon, H Bar-Joseph, G Tzarfaty, L Kuchinsky, S Rizel, ... Reproductive Biology and Endocrinology 8, 1-7, 2010 | 181 | 2010 |
The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways S Bar-Yehuda, SM Stemmer, L Madi, D Castel, A Ochaion, S Cohen, ... International journal of oncology 33 (2), 287-295, 2008 | 171 | 2008 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 161 | 2016 |